Zenbexus combo more than doubles median PFS in relapsed myeloma, BMS says

8 October 2026

US pharma major Bristol Myers Squibb (NYSE: BMY) said its Phase III EXCALIBER-RRMM trial met its progression-free survival (PFS) endpoint, with Zenbexus (iberdomide) plus daratumumab and dexamethasone (ZDd) beating daratumumab, bortezomib and dexamethasone (DVd) in relapsed or refractory multiple myeloma, including patients at first relapse.

In the 800-patient confirmatory analysis, median PFS was 42 months with ZDd against 20 months with DVd , a 51% reduction in the risk of progression or death. Median follow-up was 23 months. The open-label trial randomized 400 patients per arm. BMS said safety was consistent with previously reported findings.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



More ones to watch >






Company Spotlight



More Features in Pharmaceutical